This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -166.67% and 4.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?
by Zacks Equity Research
Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of 80% and 2.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
Cytek Biosciences, Inc. (CTKB) Stock Moves -0.33%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Cytek Biosciences, Inc. (CTKB) closed at $6.01, indicating a -0.33% shift from the previous trading day.
Cytek Biosciences (CTKB) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Cytek Biosciences (CTKB) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Cytek Biosciences (CTKB) Loses -7.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Cytek Biosciences (CTKB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Wall Street Analysts Believe Cytek Biosciences (CTKB) Could Rally 47.61%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 47.6% upside potential for Cytek Biosciences (CTKB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is it a Good Idea to Invest in ADMA Biologics (ADMA) Stock Now?
by Zacks Equity Research
Here, we discuss some reasons why investing in ADMA Biologics (ADMA) stock may turn out to be a prudent move now.
New Strong Buy Stocks for April 2nd
by Zacks Equity Research
CXDO, HITI, SIGA, CPG and CTKB have been added to the Zacks Rank #1 (Strong Buy) List on April 2, 2023.
ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q4 Earnings Expected to Decline
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cytek Biosciences, Inc. (CTKB) Surges 10.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to Decline
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for October 19th
by Zacks Equity Research
ASIX, CTKB and ERO have been added to the Zacks Rank #5 (Strong Sell) List on October 19, 2023.
Cytek Biosciences, Inc. (CTKB) Q2 Earnings Lag Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -66.67% and 6.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ultragenyx (RARE) delivered earnings and revenue surprises of -6.64% and 2.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Reports Break-Even Earnings for Q1
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of -100% and 19.73%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Soars 13.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Encompass Health (EHC) Up 32% in 6 Months: More Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is well-poised for growth on the back of growing facility count within its Inpatient Rehabilitation segment and sound liquidity position.
Here's Why Cytek Biosciences, Inc. (CTKB) is Poised for a Turnaround After Losing -16.6% in 4 Weeks
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why You Should Retain HCA Healthcare (HCA) Stock Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and sufficient cash-generating abilities.
Cytek Biosciences, Inc. (CTKB) Q4 Earnings Top Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 40% and 3.07%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Cytek Biosciences, Inc. (CTKB) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Cytek Biosciences, Inc. (CTKB) delivered earnings and revenue surprises of 100% and 6.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 7.81% and 4.14%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?